NEW YORK, Sept. 26, 2022 /PRNewswire/ -- The T-Cell Lymphoma Market size is expected to grow by USD 768.07 million during 2021-2026, at a CAGR of 8.21% during the forecast period, according to Technavio. The growing geriatric population, increasing approval of therapeutics for patients with relapsed or refractory T-cell lymphoma, and increasing incidence of T-cell lymphoma will offer immense growth opportunities.
However, stringent regulations, high cost of treatment and drug use, and a propensity for radiation therapy will challenge the growth of the market participants.
To make the most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments. Download Free Sample Report.
- Type
- Peripheral T-cell Lymphomas
- T-cell Lymphoblastic Lymphoma
- Geography
- North America
- Europe
- Asia
- Rest Of World (ROW)
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources. Our t-cell lymphoma market report covers the following areas:
- T-cell lymphoma Market size
- T-cell lymphoma Market trends
- T-cell lymphoma Market industry analysis
This study identifies technological advancements as one of the prime reasons driving the t-cell lymphoma market growth during the next few years. Buy Sample Report.
We provide a detailed analysis of around 25 vendors operating in the T-cell lymphoma Market, including some of the vendors such as vendors Backed with competitive intelligence and benchmarking, our research reports on the T-cell lymphoma Market are designed to provide entry support, customer profile, and M&As as well as go-to-market strategy support.
- AbbVie Inc.
- Accredo Health Group Inc.
- AstraZeneca Plc
- Autolus Therapeutics Plc
- Baxter International Inc.
- Biogen Inc.
- Bristol Myers Squibb Co.
- Eli Lilly and Co.
- F. Hoffmann La Roche Ltd.
- Genmab AS
- GSK Plc
- H. Lee Moffitt Cancer Center and Research Institute Inc.
- Johnson and Johnson
Find additional highlights on the growth strategies adopted by vendors and their product offerings, Download Free Sample Report.
- CAGR of the market during the forecast period
- Detailed information on factors that will assist t-cell lymphoma market growth during the next five years
- Estimation of the t-cell lymphoma market size and its contribution to the parent market
- Predictions on upcoming trends and changes in consumer behavior
- The growth of the t-cell lymphoma market
- Analysis of the market's competitive landscape and detailed information on vendors
- Comprehensive details of factors that will challenge the growth of t-cell lymphoma market vendors
Pregabalin Market by Application and Geography - Forecast and Analysis 2022-2026: The pregabalin market share is expected to increase by USD 153.03 million from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 3.74%.
Lennox-Gastaut Syndrome Treatment Market by Type and Geography - Forecast and Analysis 2022-2026: The Lennox-Gastaut Syndrome (LGS) treatment market share is expected to increase by USD 684.75 million from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 4.42%.
T-cell Lymphoma Market Scope |
|
Report Coverage |
Details |
Page number |
120 |
Base year |
2021 |
Forecast period |
2022-2026 |
Growth momentum & CAGR |
Accelerate at a CAGR of 8.21% |
Market growth 2022-2026 |
$768.07 million |
Market structure |
Fragmented |
YoY growth (%) |
7.7 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 44% |
Key consumer countries |
US, Canada, Germany, UK, and China |
Competitive landscape |
Leading companies, competitive strategies, consumer engagement scope |
Companies profiled |
AbbVie Inc., Accredo Health Group Inc., AstraZeneca Plc, Autolus Therapeutics Plc, Baxter International Inc., Biogen Inc., Bristol Myers Squibb Co., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Genmab AS, GSK Plc, H. Lee Moffitt Cancer Center and Research Institute Inc., Johnson and Johnson, Macopharma SA, Merck and Co. Inc., Mundipharma International Ltd., Novartis AG, Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd., and TYME Inc. |
Market Dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and future consumer dynamics, and market condition analysis for the forecast period. |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Browse for Technavio "Health Care" Research Reports
1 Executive Summary
- 1.1 Market overview
- Exhibit 01: Executive Summary – Chart on Market Overview
- Exhibit 02: Executive Summary – Data Table on Market Overview
- Exhibit 03: Executive Summary – Chart on Global Market Characteristics
- Exhibit 04: Executive Summary – Chart on Market by Geography
- Exhibit 05: Executive Summary – Chart on Market Segmentation by Type
- Exhibit 06: Executive Summary – Chart on Incremental Growth
- Exhibit 07: Executive Summary – Data Table on Incremental Growth
- Exhibit 08: Executive Summary – Chart on Vendor Market Positioning
2 Market Landscape
- 2.1 Market ecosystem
- Exhibit 09: Parent market
- Exhibit 10: Market Characteristics
3 Market Sizing
- 3.1 Market definition
- Exhibit 11: Offerings of vendors included in the market definition
- 3.2 Market segment analysis
- Exhibit 12: Market segments
- 3.3 Market size 2021
- 3.4 Market outlook: Forecast for 2021-2026
- Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million)
- Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
- Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
- Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)
4 Five Forces Analysis
- 4.1 Five forces summary
- Exhibit 17: Five forces analysis - Comparison between 2021 and 2026
- 4.2 Bargaining power of buyers
- Exhibit 18: Chart on Bargaining power of buyers – Impact of key factors 2021 and 2026
- 4.3 Bargaining power of suppliers
- Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026
- 4.4 Threat of new entrants
- Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026
- 4.5 Threat of substitutes
- Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026
- 4.6 Threat of rivalry
- Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026
- 4.7 Market condition
- Exhibit 23: Chart on Market condition - Five forces 2021 and 2026
5 Market Segmentation by Type
- 5.1 Market segments
- Exhibit 24: Chart on Type - Market share 2021-2026 (%)
- Exhibit 25: Data Table on Type - Market share 2021-2026 (%)
- 5.2 Comparison by Type
- Exhibit 26: Chart on Comparison by Type
- Exhibit 27: Data Table on Comparison by Type
- 5.3 Peripheral T-cell lymphomas - Market size and forecast 2021-2026
- Exhibit 28: Chart on Peripheral T-cell lymphomas - Market size and forecast 2021-2026 ($ million)
- Exhibit 29: Data Table on Peripheral T-cell lymphomas - Market size and forecast 2021-2026 ($ million)
- Exhibit 30: Chart on Peripheral T-cell lymphomas - Year-over-year growth 2021-2026 (%)
- Exhibit 31: Data Table on Peripheral T-cell lymphomas - Year-over-year growth 2021-2026 (%)
- 5.4 T-cell lymphoblastic lymphoma - Market size and forecast 2021-2026
- Exhibit 32: Chart on T-cell lymphoblastic lymphoma - Market size and forecast 2021-2026 ($ million)
- Exhibit 33: Data Table on T-cell lymphoblastic lymphoma - Market size and forecast 2021-2026 ($ million)
- Exhibit 34: Chart on T-cell lymphoblastic lymphoma - Year-over-year growth 2021-2026 (%)
- Exhibit 35: Data Table on T-cell lymphoblastic lymphoma - Year-over-year growth 2021-2026 (%)
- 5.5 Market opportunity by Type
- Exhibit 36: Market opportunity by Type ($ million)
6 Customer Landscape
- 6.1 Customer landscape overview
- Exhibit 37: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
7 Geographic Landscape
- 7.1 Geographic segmentation
- Exhibit 38: Chart on Market share by geography 2021-2026 (%)
- Exhibit 39: Data Table on Market share by geography 2021-2026 (%)
- 7.2 Geographic comparison
- Exhibit 40: Chart on Geographic comparison
- Exhibit 41: Data Table on Geographic comparison
- 7.3 North America - Market size and forecast 2021-2026
- Exhibit 42: Chart on North America - Market size and forecast 2021-2026 ($ million)
- Exhibit 43: Data Table on North America - Market size and forecast 2021-2026 ($ million)
- Exhibit 44: Chart on North America - Year-over-year growth 2021-2026 (%)
- Exhibit 45: Data Table on North America - Year-over-year growth 2021-2026 (%)
- 7.4 Europe - Market size and forecast 2021-2026
- Exhibit 46: Chart on Europe - Market size and forecast 2021-2026 ($ million)
- Exhibit 47: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
- Exhibit 48: Chart on Europe - Year-over-year growth 2021-2026 (%)
- Exhibit 49: Data Table on Europe - Year-over-year growth 2021-2026 (%)
- 7.5 Asia - Market size and forecast 2021-2026
- Exhibit 50: Chart on Asia - Market size and forecast 2021-2026 ($ million)
- Exhibit 51: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
- Exhibit 52: Chart on Asia - Year-over-year growth 2021-2026 (%)
- Exhibit 53: Data Table on Asia - Year-over-year growth 2021-2026 (%)
- 7.6 Rest of World (ROW) - Market size and forecast 2021-2026
- Exhibit 54: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
- Exhibit 55: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
- Exhibit 56: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
- Exhibit 57: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
- 7.7 US - Market size and forecast 2021-2026
- Exhibit 58: Chart on US - Market size and forecast 2021-2026 ($ million)
- Exhibit 59: Data Table on US - Market size and forecast 2021-2026 ($ million)
- Exhibit 60: Chart on US - Year-over-year growth 2021-2026 (%)
- Exhibit 61: Data Table on US - Year-over-year growth 2021-2026 (%)
- 7.8 Germany - Market size and forecast 2021-2026
- Exhibit 62: Chart on Germany - Market size and forecast 2021-2026 ($ million)
- Exhibit 63: Data Table on Germany - Market size and forecast 2021-2026 ($ million)
- Exhibit 64: Chart on Germany - Year-over-year growth 2021-2026 (%)
- Exhibit 65: Data Table on Germany - Year-over-year growth 2021-2026 (%)
- 7.9 UK - Market size and forecast 2021-2026
- Exhibit 66: Chart on UK - Market size and forecast 2021-2026 ($ million)
- Exhibit 67: Data Table on UK - Market size and forecast 2021-2026 ($ million)
- Exhibit 68: Chart on UK - Year-over-year growth 2021-2026 (%)
- Exhibit 69: Data Table on UK - Year-over-year growth 2021-2026 (%)
- 7.10 Canada - Market size and forecast 2021-2026
- Exhibit 70: Chart on Canada - Market size and forecast 2021-2026 ($ million)
- Exhibit 71: Data Table on Canada - Market size and forecast 2021-2026 ($ million)
- Exhibit 72: Chart on Canada - Year-over-year growth 2021-2026 (%)
- Exhibit 73: Data Table on Canada - Year-over-year growth 2021-2026 (%)
- 7.11 China - Market size and forecast 2021-2026
- Exhibit 74: Chart on China - Market size and forecast 2021-2026 ($ million)
- Exhibit 75: Data Table on China - Market size and forecast 2021-2026 ($ million)
- Exhibit 76: Chart on China - Year-over-year growth 2021-2026 (%)
- Exhibit 77: Data Table on China - Year-over-year growth 2021-2026 (%)
- 7.12 Market opportunity by geography
- Exhibit 78: Market opportunity by geography ($ million)
8 Drivers, Challenges, and Trends
- 8.1 Market drivers
- 8.2 Market challenges
- 8.3 Impact of drivers and challenges
- Exhibit 79: Impact of drivers and challenges in 2021 and 2026
- 8.4 Market trends
9 Vendor Landscape
- 9.1 Overview
- 9.2 Vendor landscape
- Exhibit 80: Overview on Criticality of inputs and Factors of differentiation
- 9.3 Landscape disruption
- Exhibit 81: Overview on factors of disruption
- 9.4 Industry risks
- Exhibit 82: Impact of key risks on business
10 Vendor Analysis
- 10.1 Vendors covered
- Exhibit 83: Vendors covered
- 10.2 Market positioning of vendors
- Exhibit 84: Matrix on vendor position and classification
- 10.3 AbbVie Inc.
- Exhibit 85: AbbVie Inc. - Overview
- Exhibit 86: AbbVie Inc. - Product / Service
- Exhibit 87: AbbVie Inc. - Key offerings
- 10.4 AstraZeneca Plc
- Exhibit 88: AstraZeneca Plc - Overview
- Exhibit 89: AstraZeneca Plc - Product / Service
- Exhibit 90: AstraZeneca Plc - Key news
- Exhibit 91: AstraZeneca Plc - Key offerings
- 10.5 Biogen Inc.
- Exhibit 92: Biogen Inc. - Overview
- Exhibit 93: Biogen Inc. - Product / Service
- Exhibit 94: Biogen Inc. - Key offerings
- 10.6 Bristol Myers Squibb Co.
- Exhibit 95: Bristol Myers Squibb Co. - Overview
- Exhibit 96: Bristol Myers Squibb Co. - Product / Service
- Exhibit 97: Bristol Myers Squibb Co. - Key offerings
- 10.7 F. Hoffmann La Roche Ltd.
- Exhibit 98: F. Hoffmann La Roche Ltd. - Overview
- Exhibit 99: F. Hoffmann La Roche Ltd. - Business segments
- Exhibit 100: F. Hoffmann La Roche Ltd. - Key news
- Exhibit 101: F. Hoffmann La Roche Ltd. - Key offerings
- Exhibit 102: F. Hoffmann La Roche Ltd. - Segment focus
- 10.8 GSK Plc
- Exhibit 103: GSK Plc - Overview
- Exhibit 104: GSK Plc - Business segments
- Exhibit 105: GSK Plc - Key news
- Exhibit 106: GSK Plc - Key offerings
- Exhibit 107: GSK Plc - Segment focus
- 10.9 Johnson and Johnson
- Exhibit 108: Johnson and Johnson - Overview
- Exhibit 109: Johnson and Johnson - Business segments
- Exhibit 110: Johnson and Johnson - Key news
- Exhibit 111: Johnson and Johnson - Key offerings
- Exhibit 112: Johnson and Johnson - Segment focus
- 10.10 Merck and Co. Inc.
- Exhibit 113: Merck and Co. Inc. - Overview
- Exhibit 114: Merck and Co. Inc. - Business segments
- Exhibit 115: Merck and Co. Inc. - Key news
- Exhibit 116: Merck and Co. Inc. - Key offerings
- Exhibit 117: Merck and Co. Inc. - Segment focus
- 10.11 Novartis AG
- Exhibit 118: Novartis AG - Overview
- Exhibit 119: Novartis AG - Business segments
- Exhibit 120: Novartis AG - Key offerings
- Exhibit 121: Novartis AG - Segment focus
- 10.12 Pfizer Inc.
- Exhibit 122: Pfizer Inc. - Overview
- Exhibit 123: Pfizer Inc. - Product / Service
- Exhibit 124: Pfizer Inc. - Key news
- Exhibit 125: Pfizer Inc. - Key offerings
11 Appendix
- 11.1 Scope of the report
- 11.2 Inclusions and exclusions checklist
- Exhibit 126: Inclusions checklist
- Exhibit 127: Exclusions checklist
- 11.3 Currency conversion rates for US$
- Exhibit 128: Currency conversion rates for US$
- 11.4 Research methodology
- Exhibit 129: Research methodology
- Exhibit 130: Validation techniques employed for market sizing
- Exhibit 131: Information sources
- 11.5 List of abbreviations
- Exhibit 132: List of abbreviations
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/
SOURCE Technavio
Share this article